186 related articles for article (PubMed ID: 34149741)
1. Editorial: Overcoming the Immune Microenvironment of Hepatocellular Cancer.
Shetty S; Lujambio A; Tacke F
Front Immunol; 2021; 12():707329. PubMed ID: 34149741
[No Abstract] [Full Text] [Related]
2. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
Keenan BP; Fong L; Kelley RK
J Immunother Cancer; 2019 Oct; 7(1):267. PubMed ID: 31627733
[TBL] [Abstract][Full Text] [Related]
3. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
4. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
5. New generation cancer therapy: right direction for sure with some uncertainty.
Ueno Y
Hepatol Int; 2019 Jan; 13(1):22-24. PubMed ID: 30406337
[No Abstract] [Full Text] [Related]
6. Immune-based therapies for hepatocellular carcinoma.
Pinato DJ; Guerra N; Fessas P; Murphy R; Mineo T; Mauri FA; Mukherjee SK; Thursz M; Wong CN; Sharma R; Rimassa L
Oncogene; 2020 Apr; 39(18):3620-3637. PubMed ID: 32157213
[TBL] [Abstract][Full Text] [Related]
7. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
8. Learning the Roles of the Hepatic Adaptive Immune System in Hepatocellular Carcinoma-Nature's Guide for Successful Cancer Immunotherapy.
Heikenwälder M; Pikarsky E
Semin Liver Dis; 2017 Aug; 37(3):210-218. PubMed ID: 28847032
[No Abstract] [Full Text] [Related]
9. A new perspective on the immune escape mechanism in HCC: onco-foetal reprogramming.
Chew SC; Choo SY; Chow PK
Br J Cancer; 2021 Jun; 124(12):1897-1899. PubMed ID: 33767421
[TBL] [Abstract][Full Text] [Related]
10. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications.
Cariani E; Missale G
Liver Int; 2019 Sep; 39(9):1608-1621. PubMed ID: 31314948
[TBL] [Abstract][Full Text] [Related]
11. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
12. Cancer vaccines for hepatocellular carcinoma: future directions.
Buonaguro FM; Buonaguro L
Immunotherapy; 2016; 8(4):391-3. PubMed ID: 26973120
[No Abstract] [Full Text] [Related]
13. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
[TBL] [Abstract][Full Text] [Related]
14. Immune control in hepatocellular carcinoma development and progression: role of stromal cells.
Sprinzl MF; Galle PR
Semin Liver Dis; 2014 Nov; 34(4):376-88. PubMed ID: 25369300
[TBL] [Abstract][Full Text] [Related]
15. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
Montella L; Sarno F; Ambrosino A; Facchini S; D'Antò M; Laterza MM; Fasano M; Quarata E; Ranucci RAN; Altucci L; Berretta M; Facchini G
Cells; 2021 Jul; 10(8):. PubMed ID: 34440678
[TBL] [Abstract][Full Text] [Related]
16. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
Roth GS; Decaens T
Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
[TBL] [Abstract][Full Text] [Related]
17. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
Xia Y; Brown ZJ; Huang H; Tsung A
Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in hepatocellular carcinoma.
Buonaguro L; Mauriello A; Cavalluzzo B; Petrizzo A; Tagliamonte M
Ann Hepatol; 2019; 18(2):291-297. PubMed ID: 31047849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]